Physician profile
Mitchell J Gold
NPI 1447223565
$1,341.90
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $197 · 2021: $341 · 2022: $380.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $297.70 | 2021-2022 | |
| Philips North America LLC | $156.37 | 2019-2020 | |
| Amgen INC. | $136.33 | 2019-2022 | |
| Astellas Pharma US INC | $100.66 | 2019-2020 | |
| Topcon Healthcare Solutions, INC. | $70.69 | 2019 | |
| Pfizer INC. | $62.49 | 2019-2020 | |
| Allergan, INC. | $48.52 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.41 | 2019-2021 | |
| Abbott Laboratories | $41.20 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.86 | 2019-2021 | |
| Amarin Pharma, INC. | $33.26 | 2019-2020 | |
| Glaxosmithkline, LLC. | $30.63 | 2021-2022 | |
| Horizon Therapeutics Plc | $27.20 | 2021-2022 | |
| Grifols USA, LLC | $26.00 | 2020 | |
| Jazz Pharmaceuticals INC. | $24.15 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $23.23 | 2021 | |
| Gilead Sciences, INC. | $20.19 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.39 | 2021 | |
| Radius Health, INC. | $16.41 | 2021 | |
| Lilly USA, LLC | $16.06 | 2022 | |
| Medtronic Minimed, INC. | $16.01 | 2019 | |
| Novo Nordisk INC | $14.53 | 2022 | |
| Eisai INC. | $14.41 | 2022 | |
| Lucid Diagnostics INC. | $14.14 | 2022 | |
| Currax Pharmaceuticals LLC | $13.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.53 | 2022 | |
| Shield Therapeutics INC | $13.26 | 2022 | |
| Tactile Systems Technology INC | $12.60 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.